U.S. Retail REITs Stock News

Byrna Technologies has reported preliminary guidance for its fiscal fourth quarter and full year 2025, expecting US$35.1 million in quarterly revenue and US$118.0 million for the year, reflecting strong dealer, chain store, direct-to-consumer, and international performance compared with 2024. The company’s decision to ring the Nasdaq Opening Bell in December 2025 underscores how its expanding retail footprint, successful Byrna CL launch, and heightened brand visibility are becoming central...

If you are wondering whether V.F is a beaten-down bargain or a value trap at this point in the cycle, you are not alone. That is exactly what this breakdown is here to unpack. After a long slide, including a -73.7% return over 5 years and -14.5% over the last year, the stock has shown some life with a sharp 26.9% jump over the past month, despite being down -13.6% year to date and -5.3% in the last week. That recent rebound has come as investors focus on V.F's ongoing portfolio reshaping and...

Amcor (NYSE:AMCR) just confirmed it will move ahead with a 1 for 5 reverse stock split in mid January 2026, a structural shift that will immediately reshape the share count and optics. See our latest analysis for Amcor. That move lands after a choppy stretch where the 1 year total shareholder return is down 6.6 percent, and the year to date share price return of negative 11.3 percent signals fading momentum despite underlying earnings growth. If this shake up has you rethinking where to look...

BeOne Medicines (ONC) is back in focus after the FDA granted Fast Track Designation to its liver cancer bispecific BGB-B2033 and accepted sonrotoclax for Priority Review, underscoring real momentum across its oncology pipeline. See our latest analysis for BeOne Medicines. Those back to back FDA milestones have arrived after a choppy few weeks, with a 30 day share price return of minus 10.7 percent but a powerful year to date share price gain of 71.8 percent. This suggests underlying momentum...

If you are wondering whether Redwire at around $8 is a bruised bargain or a value trap, you are not alone. That is exactly what we are going to unpack here. The stock has bounced sharply in the short term, up 9.7% over the last week and 46.0% over the last month, but it is still down 53.1% year to date and 42.4% over the past year, even after a huge 316.7% gain over three years. Those kinds of swings have come alongside a steady stream of space infrastructure contract wins and strategic...

If you have been wondering whether Herbalife at around $13.99 is a bargain or a value trap, you are not alone. This breakdown is designed to help you cut through the noise. The stock has been on a wild ride, dropping about 5.1% over the last week but still up 51.7% over the past month and 109.4% year to date, with a 115.9% gain over the last year despite a 71.1% slide over five years. Recent coverage has highlighted how investors are reassessing Herbalife's long term prospects in light of...

In recent days, SES AI Corporation and Korea-based Top Material announced plans to collaborate on expanding lithium-metal and lithium-ion cell manufacturing capacity in Korea for drones and urban air mobility, aiming to build an NDAA-compliant, cost-efficient supply chain under a non-binding agreement targeting a definitive deal by early 2026. SES AI also outlined plans to nearly triple output at its Chungju plant to around 1 million AI-enabled pouch cells annually, highlighting how drones...

The story around SPS Commerce (SPSC) shifted quickly after activist investor Anson disclosed a stake and began pushing for a potential sale, just months after the Carbon6 deal ran into new Amazon marketplace headwinds. See our latest analysis for SPS Commerce. The activist push has arrived after a bruising stretch for investors, with the share price down sharply year to date, even after a 16.1 percent 1 month share price return that hints at stabilizing sentiment and potential re rating if...

Investor anxiety over a potential AI bubble has dragged Zeta Global Holdings (ZETA) into the latest tech selloff, as warnings about shrinking margins push traders to rotate from high growth software names into steadier corners of the market. See our latest analysis for Zeta Global Holdings. Even with the recent AI jitters weighing on sentiment, Zeta’s latest close at $17.99 leaves it with a mildly negative year to date share price return. Its three year total shareholder return of 119.12...

Celldex Therapeutics (CLDX) has been back on traders radar after a recent bump in the share price, leaving many investors wondering whether this clinical stage biotech is quietly setting up for its next move. See our latest analysis for Celldex Therapeutics. With the latest uptick to about $25.60, Celldex’s 30 day share price return of 2.73 percent and modest 90 day gain hint at cautiously improving momentum, even as the 3 year total shareholder return of negative 41.96 percent reminds...

Flowserve (FLS) has quietly rewarded patient shareholders, with the stock up about 24% over the past year and roughly 25% in the past 3 months, outpacing many industrial peers. See our latest analysis for Flowserve. With the share price now around $71, Flowserve has built steady momentum, with a strong 90 day share price return and a standout three year total shareholder return that point to rising confidence in its long term prospects. If Flowserve’s run has you rethinking your watchlist,...

The Trade Desk (TTD) just announced a small round of layoffs, trimming less than 1% of its staff, a follow up to last year's larger restructuring as the ad tech environment continues to tighten. See our latest analysis for Trade Desk. Those small cuts sit against a much tougher backdrop, with the 1 year share price return down around 70 percent as investors reassess growth and competitive risks, even though Trade Desk is still growing revenue and margins. As a result, sentiment looks more...

Wondering if Match Group at around $33 is a hidden bargain or a value trap in the making? This article will walk you through the numbers in plain language so you can decide for yourself. Despite a modest 4.8% gain over the last 30 days and being up 1.3% year to date, the stock is still roughly flat over the past year and sits far below its 5 year highs. That keeps both value hunters and skeptics interested. Recent headlines have focused on Match Group sharpening its product strategy and...

Leidos Holdings has appointed Theodore "Ted" Tanner Jr. as its new chief technology officer, effective January 5, 2026, bringing experience from BigBear.ai, IBM Watson Health, and several AI-focused startups, while outgoing CTO Jim Carlini will remain as a senior advisor on national security. Tanner’s background in artificial intelligence, machine learning, and cloud technologies, underscored by 18 U.S. patents and work across defense and healthcare, signals a deeper push by Leidos into...

KB Home (KBH) has wrapped up FY 2025 with fourth quarter revenue of about $1.7 billion and basic EPS of roughly $1.59, setting a clear marker for how its homebuilding cycle is playing out amid softer profitability trends over the past year. The company has seen quarterly revenue ease from around $2.0 billion and EPS of about $2.59 in Q4 2024 to $1.7 billion and $1.59 in Q4 2025, while trailing net profit margins have compressed. This puts the spotlight firmly on how sustainable its current...

Iovance Biotherapeutics (IOVA) is back in the spotlight after fresh FDA related progress on its lifileucel cancer therapy and a Phase 2 melanoma update. These developments are reshaping how investors are sizing up the stock. See our latest analysis for Iovance Biotherapeutics. Those FDA tailwinds and trial updates have sparked a sharp turnaround in sentiment. The latest share price of $2.48 is supported by a 7 day share price return of 12.73 percent and a 90 day share price return of 20.98...

United Therapeutics (UTHR) has been drawing fresh attention after progress in its xenotransplantation studies and stronger financial results, a combination that is quietly reshaping how many investors frame the long term story. See our latest analysis for United Therapeutics. Those xenotransplantation milestones and solid earnings have coincided with a powerful move in the stock, with a year to date share price return above 40 percent and five year total shareholder return above 200 percent,...

On December 10, 2025, Honeywell International announced that former PepsiCo Chair and CEO Indra Nooyi will join its board as an independent director effective January 1, 2026, bringing extensive global leadership and governance experience. Her simultaneous board roles at Amazon and Philips suggest Honeywell is prioritizing seasoned oversight as it reshapes its portfolio and governance ahead of major business separations. We’ll now examine how Indra Nooyi’s appointment and Honeywell’s broader...

Setting the scene for Luda Technology Group's latest results Luda Technology Group (LUD) opened H1 2025 with trailing 12 month revenue of about $37.1 million and basic EPS of roughly negative $0.08, reflecting unprofitable operations over the period. The company has seen reported half year revenue move from $26.3 million in H2 2023 to $24.9 million in H1 2024, then down to $19.9 million in H2 2024, while basic EPS shifted from $0.04 to $0.05 before slipping to negative $0.07 alongside net...

Northrop Grumman (NOC) has quietly kept investors interested this year, with the stock up about 21% year to date and roughly 23% over the past year, outpacing many defense peers. See our latest analysis for Northrop Grumman. At a share price of $568.46, Northrop Grumman has seen steady upward momentum this year, with a strong year to date share price return contributing to a robust one year total shareholder return as investors warm to its growth pipeline and perceived resilience. If Northrop...

Klarna Group (KLAR) shares have been drifting after a weak past 3 months, and that slide now has investors asking whether the company’s improving growth profile justifies stepping in at current levels. See our latest analysis for Klarna Group. The latest $30.78 share price may look subdued after a sharp 90 day share price return of negative 28.44 percent and weak year to date performance, but that pullback follows brisk revenue and earnings momentum that has investors reassessing both growth...

If you have been wondering whether Carnival Corporation and stock is still a bargain after its rebound, you are not alone. This article will unpack what the current share price really implies about future cruises and cash flows. The stock has climbed 12.7% over the last week, 19.3% over the past month, and is now up 24.4% year to date. This builds on a 298.5% gain over three years that has significantly changed how investors view its risk and recovery story. Recent headlines have focused on...

If you have been wondering whether Medtronic is still a buy at around $98 a share, you are not alone. This article is designed to unpack what that price really implies about the company’s value. The stock is down about 1.2% over the last week and 1.7% over the last month, but it is still up 22.9% year to date and 25.7% over the past year, which signals a meaningful shift in how the market is viewing its long term prospects. Recent headlines have focused on Medtronic’s push to streamline its...

Expeditors International of Washington (EXPD) has quietly delivered strong gains this year, with the stock up about 39% year to date and roughly 27% over the past 3 months, outpacing many logistics peers. See our latest analysis for Expeditors International of Washington. The latest move to around $152 per share caps a steady run, with a near 10% 1 month share price return adding to an already strong year of building momentum. If you want to see what other logistics-like trends are playing...